Galderma, known by plastic and cosmetic surgeons for such popular brands as Restylane, Dysport (abobotulinumtoxinA) and Sculptra Aesthetic, and CoolSculpting’s parent company ZELTIQ, announced early in December that the companies are collaborating on their aesthetic businesses.
"The ZELTIQ and Galderma collaboration presents a significant opportunity for cosmetic dermatologists and plastic surgeons who utilize CoolSculpting and aesthetic injectables, like Dysport. The partnership is designed to better serve healthcare providers and their patients by increasing awareness of these treatments, providing the opportunity for new patients to access and experience them through promotions, and helping grow and build the profile of the practice,” ZELTIQ CEO, Mark Foley tells Cosmetic Surgery Times.
Related: Aesthetics powerhouse Allergan merges with R&D-rich Pfizer
The collaboration, effective immediately, is not a merger, says a ZELTIQ spokesperson. Rather, each company will still remain the same, but will collaborate to promote especially CoolSculpting and Dysport. This includes creating connections between loyalty programs associated with Galderma’s aesthetic brands and ZELTIQ's CoolSculpting procedure.
"I am pleased this collaboration will result in greater access to these valuable products, as well as added benefits for my practice and patients through the ASPIRE Galderma Rewards and Crystal Rewards loyalty programs,” said Marina Del Rey, Calif., plastic surgeon Grant Stevens, M.D., in a press release about the collaboration.
